Pontifax Venture, a healthcare-focused venture capital firm, led a €31m Series A extension round in Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates for the treatment of cancers, with participation from Pontifax Venture, Novo, Ysios Capital, RA Capital and HealthCap and Gilde Healthcare. “We are excited to support Adcendo’s efforts to bring new treatments to patients with cancer as we continue our focus on seeking exciting transformative technologies to treat substantial unmet medical need indications. Adcendo’s ADC capabilities offer significant potential and I look forward to closely working with the team to develop their pipeline assets and bring innovative therapies to patients in need,” Ohad Hammer, Pontifax Venture Partner.